Data sources and overview of comparative analysis for Harvard and PRIME models
| Feature | Harvard | PRIME |
| Model structure | Proportional outcomes | Proportional outcomes |
| Population representation | Open, multi-cohort | Open, multi-cohort |
| Representation of infection | Static | Static |
| Representation of cancer progression | Country-specific distributions of cancer stages, assuming 2 years lived with disability and 5 years survival for individuals experiencing cancer mortality21 | Based on Global Burden of Disease-prescribed durations and phases (diagnosis and primary treatment phase, controlled phase, metastatic phase and terminal phase) |
| Disability-adjusted life year estimation | Based on weighted averages of Global Burden of Disease-prescribed weights for Stages I–III and Stage IV34 35 | Based on Global Burden of Disease-prescribed weights35 |
| Cervical cancer incidence | Globocan 2020 database of IARC11 | Globocan 2020 database of IARC11 |
| Cervical cancer mortality | Weighted averages of 5 year stage-specific survival probabilities for untreated and treated cervical cancers (by region) and treatment access proportions (by country)11 21 | Globocan 2020 database of IARC11 |
| Cervical cancer prevalence | Not applicable | Globocan 2020 database of IARC11 |
| Population size | United Nations World Population Prospects 2019 estimates36 | United Nations World Population Prospects 2019 estimates combined with time-varying, country-specific probability of death for projected estimates36 |
| Life tables | World Health Organization 2019 life tables (constant)37 | Constructed with United Nations Population Division time-varying, country-specific probability of death36 |
| HPV-16/18 proportion | Meta-analysis by IARC32 | Serrano et al31 based on meta-analysis by IARC32 and retrospective cross-sectional study33 |
HPV, human papillomavirus; IARC, International Agency for Research on Cancer; PRIME, Papillomavirus Rapid Interface for Modelling and Economics.